As reported in prominent industry group RAPS (Regulatory Affairs Professionals Society) and their Regulatory Focus, Regulatory Roundup Asia, New Zealand has revised their clinical trial rules following positive industry and public feedback. According to RAPS, New Zealand regulatory agency bodies (The New Zealand Medicines and Medical Devices Safety Authority (Medsafe) revised its clinical trials guidelines. Their recent revision drafts received positive feedback from industry during the standard comment period. Key industry participants included AbbVie, Boehringer Ingelheim, Roche and trade association, Medicines New Zealand. RAPS Regulatory Focus has produced timely, high quality clinical regulatory coverage for a long time and we recommend bookmarking the website (see link below) should global regulatory requirements be of interest.